Jubilant Ingrevia Ltd is Rated Sell

Feb 04 2026 10:10 AM IST
share
Share Via
Jubilant Ingrevia Ltd is rated 'Sell' by MarketsMojo, with this rating last updated on 12 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Jubilant Ingrevia Ltd is Rated Sell

Current Rating Overview

On 12 January 2026, MarketsMOJO revised its assessment of Jubilant Ingrevia Ltd, assigning it a 'Sell' rating. This change was accompanied by a significant drop in the Mojo Score, which fell by 21 points from 61 to 40, signalling a more cautious stance towards the stock. The 'Sell' rating indicates that, based on a comprehensive evaluation of various factors, the stock is expected to underperform relative to the broader market or its sector peers in the near to medium term.

Here’s How the Stock Looks Today

As of 04 February 2026, the stock shows a mixed but predominantly cautious picture. The company’s market capitalisation remains in the smallcap category within the Specialty Chemicals sector, a segment known for its cyclical nature and sensitivity to global economic shifts. Investors should note that all financial data and returns discussed here are current as of this date, ensuring an accurate reflection of the stock’s present condition.

Quality Assessment

Jubilant Ingrevia’s quality grade is assessed as average. This suggests that while the company maintains a stable operational framework, it lacks standout attributes in areas such as profitability consistency, competitive advantage, or innovation leadership. The operating profit growth rate over the past five years has been negative, at an annualised rate of -5.79%, indicating challenges in sustaining long-term earnings momentum. This sluggish growth undermines confidence in the company’s ability to generate robust returns over time.

Valuation Perspective

The valuation grade is considered fair, implying that the stock is neither significantly undervalued nor overvalued relative to its fundamentals and sector peers. Investors should interpret this as a neutral signal, where the current price reflects the company’s earnings potential and risks without offering a compelling margin of safety or premium. Given the subdued growth prospects, the fair valuation suggests limited upside potential from a price appreciation standpoint.

Financial Trend Analysis

Financially, Jubilant Ingrevia exhibits a positive trend, which is a noteworthy counterbalance to other concerns. This indicates that recent financial metrics such as revenue, cash flow, or debt management have shown improvement or stability. However, this positive trend has not yet translated into strong stock performance, as evidenced by the returns data. The stock has delivered a negative return of -9.45% over the past year and has underperformed the BSE500 index over one year, three years, and three months, signalling that market sentiment remains subdued despite some financial improvements.

Technical Outlook

The technical grade is bearish, reflecting a downtrend in the stock’s price movement and negative momentum indicators. Recent price action shows a 1-day decline of -1.6%, a 1-month drop of -9.78%, and a 6-month decrease of -12.29%. These figures highlight persistent selling pressure and a lack of short-term buying interest. Technical analysis suggests that the stock may continue to face resistance at current levels, making it less attractive for traders seeking momentum or quick gains.

Stock Returns and Market Performance

Currently, the company’s financial metrics indicate underperformance relative to broader market benchmarks. The stock’s year-to-date return stands at -6.86%, and its 3-month return is -4.90%. Over the last week, however, the stock showed a modest recovery with a gain of +3.31%, which may reflect short-term volatility rather than a sustained turnaround. The long-term negative operating profit growth and consistent underperformance against the BSE500 index reinforce the cautious stance embedded in the 'Sell' rating.

Implications for Investors

For investors, the 'Sell' rating on Jubilant Ingrevia Ltd serves as a cautionary signal. It suggests that the stock currently carries risks that outweigh its potential rewards, particularly given its average quality, fair valuation, bearish technical outlook, and mixed financial trends. Investors should carefully consider these factors in the context of their portfolio objectives and risk tolerance. Those seeking growth or stability may find more compelling opportunities elsewhere, while value investors might await clearer signs of operational turnaround or valuation improvement before committing capital.

Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!

  • - Fresh momentum detected
  • - Explosive short-term signals
  • - Early wave positioning

Catch the Wave Now →

Sector and Market Context

Operating within the Specialty Chemicals sector, Jubilant Ingrevia faces industry-specific challenges such as raw material price volatility, regulatory pressures, and global demand fluctuations. The sector often rewards companies with strong innovation pipelines and cost efficiencies, areas where Jubilant Ingrevia’s average quality rating suggests room for improvement. The smallcap status also implies higher volatility and liquidity risks compared to larger peers, factors that investors should weigh carefully.

Conclusion

In summary, Jubilant Ingrevia Ltd’s current 'Sell' rating by MarketsMOJO reflects a comprehensive evaluation of its present fundamentals, valuation, financial trends, and technical outlook as of 04 February 2026. While the company shows some positive financial trends, these are overshadowed by weak long-term growth, bearish technical signals, and underwhelming stock returns. Investors are advised to approach the stock with caution and consider alternative opportunities that better align with their investment goals and risk appetite.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News